Myeloma: VRd Plus Isatuximab Improves Outcomes

Adding an anti-CD38 monoclonal antibody to the standard first-line treatment improved outcomes in new, transplant-ineligible multiple myeloma patients in a phase 3 trial analysis.
MDedge News